This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703–1708.
Gowin KL, Mesa RA . Profile of pomalidomide and its potential in the treatment of myelofibrosis. Ther Clin Risk Manag 2015; 11: 549–556.
Pardanani A, Begna K, Finke C, Lasho T, Tefferi A . Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis. Am J Hematol 2011; 86: 343–345.
Tefferi A, Al-Ali H, Barosi B, Devos T, Gisslinger H, Jiang Q et al. A randomized study of pomalidomide vs. placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and rbc-transfusion-dependence. Leukemia, e-pub ahead of print 18 November 2016.
Schlenk RF, Stegelmann F, Reiter A, Jost E, Gattermann N, Hebart H et al. Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis. Leukemia; e-pub ahead of print 29 November 2016.
Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799–807.
Cervantes F, Alvarez-Larran A, Hernandez-Boluda JC, Sureda A, Torrebadell M, Montserrat E . Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol 2004; 127: 399–403.
Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013; 27: 1322–1327.
Tefferi A, Lasho TL, Begna KH, Patnaik MM, Zblewski DL, Finke CM et al. A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. N Engl J Med 2015; 373: 908–919.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
DMR reports clinical trial or research funding from Celgene, Gilead, and Novartis to his institution. He has received honoraria from Novartis.
Rights and permissions
About this article
Cite this article
Ross, D. Responses to pomalidomide and placebo in myelofibrosis-related anaemia. Leukemia 31, 532–533 (2017). https://doi.org/10.1038/leu.2016.348
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2016.348
This article is cited by
-
Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors
Current Hematologic Malignancy Reports (2022)
-
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
Leukemia (2018)